Guggenheim lowers Eli Lilly stock price target on GLP-1 market uncertainty

Eli Lilly (LLY) reported strong Q2 2025 results, surpassing expectations and raising full-year guidance, yet investor attention and Guggenheim's revised price target of $875 (from $942) were driven by Phase 3 clinical trial data for its oral obesity drug, orforglipron, which came in slightly below the firm's expectations. This, coupled with broader GLP-1 market competitive uncertainties and a Texas Attorney General lawsuit, has created mixed analyst reactions and places LLY in a "show me" period as it navigates pipeline development and awaits further key data readouts.

Analysis

Eli Lilly (LLY) presents a dichotomous profile, pairing exceptional financial performance with significant pipeline uncertainty and legal challenges. The company reported a robust 36.8% year-over-year revenue growth and surpassed second-quarter 2025 earnings expectations, prompting a raised full-year guidance and eight upward analyst estimate revisions. Despite these strong fundamentals, investor focus and negative sentiment have been driven by clinical trial data for its oral obesity drug, orforglipron. The ATTAIN-1 trial's weight loss results fell short of expectations from Guggenheim, which consequently lowered its price target to $875 from $942, citing uncertainty around pricing and competitive dynamics for key GLP-1 assets like tirzepatide and orforglipron. This has placed the company in a "show me" period, with significant attention on upcoming data readouts. Adding to the complexity is a lawsuit from the Texas Attorney General concerning the marketing of its GLP-1 drugs. The situation has resulted in mixed analyst sentiment, with firms like JPMorgan and Morgan Stanley maintaining high price targets of $1,100 and $1,135 respectively, while Guggenheim and UBS have moderated their targets, reflecting the deep uncertainty surrounding the evolution of the highly competitive GLP-1 market.

Key Decisions for Investors

• Investors should monitor key upcoming catalysts, particularly the full data from the SURPASS-CVOT and ATTAIN-1 trials in September and the highly anticipated first Phase 3 retatrutide readout in the fourth quarter of 2025, which are likely to be major drivers of the stock's performance.
• Given the high P/E ratio of 41.5, investors must weigh the company's proven financial strength and raised guidance against the potential for valuation compression from disappointing clinical data or intensifying competition in the GLP-1 market.
• The ongoing lawsuit from the Texas Attorney General represents a material non-clinical risk that requires careful monitoring, as any adverse developments could impact sentiment and add financial liability.
• Consider the divergence in analyst price targets, ranging from $875 to $1,135, as an indicator of the high uncertainty and the wide range of potential outcomes for the company's pipeline and market position.